Skip to main content
Top
Published in: European Journal of Nutrition 1/2019

Open Access 01-02-2019 | Original Contribution

Effects of hydration on plasma copeptin, glycemia and gluco-regulatory hormones: a water intervention in humans

Authors: Sofia Enhörning, Irina Tasevska, Ronan Roussel, Nadine Bouby, Margaretha Persson, Philippe Burri, Lise Bankir, Olle Melander

Published in: European Journal of Nutrition | Issue 1/2019

Login to get access

Abstract

Purpose

High plasma copeptin, a marker of vasopressin, predicts diabetes mellitus. We tested if copeptin could be suppressed by increased water intake in healthy individuals, and if a water-induced change in copeptin was accompanied by altered concentrations of glucose, insulin or glucagon.

Methods

Thirty-nine healthy individuals underwent, in random order, 1 week of high water intake (3 L/day on top of habitual intake) and 1 week of normal (habitual) fluid intake (control). Fasting plasma concentrations of copeptin, glucose, insulin and glucagon were compared between the ends of both periods. Furthermore, acute copeptin kinetics were mapped for 4 h after ingestion of 1 L of water.

Results

After acute intake of 1 L water, copeptin was significantly reduced within 30 min, and reached maximum reduction within 90 min with on average 39% reduction (95% confidence interval (95 CI) 34–45) (p < 0.001) and remained low the entire test period (4 h). One week of increased water intake led to a 15% reduction (95 CI 5–25) (p = 0.003) of copeptin compared to control week. The greatest reduction occurred among subjects with habitually high copeptin and concentrated urine (“water-responders”). Water-responders had significant water-induced reduction of glucagon, but glucose and insulin were unaffected.

Conclusions

Both acute and 1 week extra water intake potently reduced copeptin concentration. In those with the greatest decline (water-responders), who are typically low drinkers with high baseline copeptin, water induced a reduction in fasting glucagon. Long-term trials assessing the effect of water on glucometabolic traits should focus on low-water drinkers with high copeptin concentration.
Appendix
Available only for authorised users
Literature
1.
go back to reference Whitton PD, Rodrigues LM, Hems DA (1978) Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. Biochem J 176:893–898CrossRefPubMedPubMedCentral Whitton PD, Rodrigues LM, Hems DA (1978) Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. Biochem J 176:893–898CrossRefPubMedPubMedCentral
2.
go back to reference Keppens S, de Wulf H (1979) The nature of the hepatic receptors involved in vasopressin-induced glycogenolysis. Biochim Biophys Acta 588:63–69CrossRefPubMed Keppens S, de Wulf H (1979) The nature of the hepatic receptors involved in vasopressin-induced glycogenolysis. Biochim Biophys Acta 588:63–69CrossRefPubMed
3.
go back to reference Abu-Basha EA, Yibchok-Anun S, Hsu WH (2002) Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism 51:1184–1190CrossRefPubMed Abu-Basha EA, Yibchok-Anun S, Hsu WH (2002) Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism 51:1184–1190CrossRefPubMed
4.
go back to reference Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu TA, Mori T, Tsujimoto G (2004) The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Investig 113:302–309CrossRefPubMed Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu TA, Mori T, Tsujimoto G (2004) The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Investig 113:302–309CrossRefPubMed
5.
go back to reference Perraudin V, Delarue C, Lefebvre H, Contesse V, Kuhn JM, Vaudry H (1993) Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of V1 receptors. J Clin Endocrinol Metab 76:1522–1528PubMed Perraudin V, Delarue C, Lefebvre H, Contesse V, Kuhn JM, Vaudry H (1993) Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of V1 receptors. J Clin Endocrinol Metab 76:1522–1528PubMed
6.
go back to reference Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A (2012) Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev 92:1813–1864CrossRefPubMed Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A (2012) Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev 92:1813–1864CrossRefPubMed
7.
go back to reference Baumann G, Dingman JF (1976) Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Investig 57:1109–1116CrossRefPubMed Baumann G, Dingman JF (1976) Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Investig 57:1109–1116CrossRefPubMed
8.
go back to reference Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52:112–119CrossRefPubMed Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52:112–119CrossRefPubMed
9.
go back to reference Balanescu S, Kopp P, Gaskill MB, Morgenthaler NG, Schindler C, Rutishauser J (2011) Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States. J Clin Endocrinol Metab 96:1046–1052CrossRefPubMed Balanescu S, Kopp P, Gaskill MB, Morgenthaler NG, Schindler C, Rutishauser J (2011) Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States. J Clin Endocrinol Metab 96:1046–1052CrossRefPubMed
10.
go back to reference Roussel R, Fezeu L, Marre M, Velho G, Fumeron F, Jungers P, Lantieri O, Balkau B, Bouby N, Bankir L, Bichet DG (2014) Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab 99:4656–4663CrossRefPubMed Roussel R, Fezeu L, Marre M, Velho G, Fumeron F, Jungers P, Lantieri O, Balkau B, Bouby N, Bankir L, Bichet DG (2014) Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab 99:4656–4663CrossRefPubMed
11.
go back to reference Enhorning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgenthaler NG, Bergmann A, Lindholm E, Groop L, Lyssenko V, Orho-Melander M, Newton-Cheh C, Melander O (2010) Plasma copeptin and the risk of diabetes mellitus. Circulation 121:2102–2108CrossRefPubMedPubMedCentral Enhorning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgenthaler NG, Bergmann A, Lindholm E, Groop L, Lyssenko V, Orho-Melander M, Newton-Cheh C, Melander O (2010) Plasma copeptin and the risk of diabetes mellitus. Circulation 121:2102–2108CrossRefPubMedPubMedCentral
12.
go back to reference Abbasi A, Corpeleijn E, Meijer E, Postmus D, Gansevoort RT, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJ (2012) Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia 55:1963–1970CrossRefPubMed Abbasi A, Corpeleijn E, Meijer E, Postmus D, Gansevoort RT, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJ (2012) Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia 55:1963–1970CrossRefPubMed
13.
go back to reference Wannamethee SG, Welsh P, Papacosta O, Lennon L, Whincup PH, Sattar N (2015) Copeptin, insulin resistance, and risk of incident diabetes in older men. J Clin Endocrinol Metab 100:3332–3339CrossRefPubMedPubMedCentral Wannamethee SG, Welsh P, Papacosta O, Lennon L, Whincup PH, Sattar N (2015) Copeptin, insulin resistance, and risk of incident diabetes in older men. J Clin Endocrinol Metab 100:3332–3339CrossRefPubMedPubMedCentral
14.
go back to reference Enhorning S, Struck J, Wirfalt E, Hedblad B, Morgenthaler NG, Melander O (2011) Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab 96:E1065–E1072CrossRefPubMed Enhorning S, Struck J, Wirfalt E, Hedblad B, Morgenthaler NG, Melander O (2011) Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab 96:E1065–E1072CrossRefPubMed
15.
go back to reference Enhorning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, Morgenthaler NG, Nilsson PM, Melander O (2013) Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmo Diet and Cancer Study cardiovascular cohort. Int J Obes 37:598–603CrossRef Enhorning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, Morgenthaler NG, Nilsson PM, Melander O (2013) Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmo Diet and Cancer Study cardiovascular cohort. Int J Obes 37:598–603CrossRef
16.
go back to reference Enhorning S, Hedblad B, Nilsson PM, Engstrom G, Melander O (2015) Copeptin is an independent predictor of diabetic heart disease and death. Am Heart J 169:549–556 e541CrossRefPubMedPubMedCentral Enhorning S, Hedblad B, Nilsson PM, Engstrom G, Melander O (2015) Copeptin is an independent predictor of diabetic heart disease and death. Am Heart J 169:549–556 e541CrossRefPubMedPubMedCentral
17.
go back to reference Tasevska I, Enhorning S, Persson M, Nilsson PM, Melander O (2016) Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart 102:127–132CrossRefPubMed Tasevska I, Enhorning S, Persson M, Nilsson PM, Melander O (2016) Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart 102:127–132CrossRefPubMed
18.
go back to reference Velho G, El Boustany R, Lefevre G, Mohammedi K, Fumeron F, Potier L, Bankir L, Bouby N, Hadjadj S, Marre M, Roussel R (2016) Plasma copeptin, kidney outcomes, ischemic heart disease, and all-cause mortality in people with long-standing type 1 diabetes. Diabetes Care 39:2288–2295CrossRefPubMed Velho G, El Boustany R, Lefevre G, Mohammedi K, Fumeron F, Potier L, Bankir L, Bouby N, Hadjadj S, Marre M, Roussel R (2016) Plasma copeptin, kidney outcomes, ischemic heart disease, and all-cause mortality in people with long-standing type 1 diabetes. Diabetes Care 39:2288–2295CrossRefPubMed
19.
go back to reference Johnson EC, Munoz CX, Jimenez L, Le Bellego L, Kupchak BR, Kraemer WJ, Casa DJ, Maresh CM, Armstrong LE (2016) Hormonal and thirst modulated maintenance of fluid balance in young women with different levels of habitual fluid consumption. Nutrients 8: 302CrossRefPubMedCentral Johnson EC, Munoz CX, Jimenez L, Le Bellego L, Kupchak BR, Kraemer WJ, Casa DJ, Maresh CM, Armstrong LE (2016) Hormonal and thirst modulated maintenance of fluid balance in young women with different levels of habitual fluid consumption. Nutrients 8: 302CrossRefPubMedCentral
20.
go back to reference Taveau C, Chollet C, Waeckel L, Desposito D, Bichet DG, Arthus MF, Magnan C, Philippe E, Paradis V, Foufelle F, Hainault I, Enhorning S, Velho G, Roussel R, Bankir L, Melander O, Bouby N (2015) Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia 58:1081–1090CrossRefPubMed Taveau C, Chollet C, Waeckel L, Desposito D, Bichet DG, Arthus MF, Magnan C, Philippe E, Paradis V, Foufelle F, Hainault I, Enhorning S, Velho G, Roussel R, Bankir L, Melander O, Bouby N (2015) Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia 58:1081–1090CrossRefPubMed
21.
go back to reference Chan J, Knutsen SF, Blix GG, Lee JW, Fraser GE (2002) Water, other fluids, and fatal coronary heart disease: the Adventist Health Study. Am J Epidemiol 155:827–833CrossRefPubMed Chan J, Knutsen SF, Blix GG, Lee JW, Fraser GE (2002) Water, other fluids, and fatal coronary heart disease: the Adventist Health Study. Am J Epidemiol 155:827–833CrossRefPubMed
22.
go back to reference Dennis EA, Dengo AL, Comber DL, Flack KD, Savla J, Davy KP, Davy BM (2010) Water consumption increases weight loss during a hypocaloric diet intervention in middle-aged and older adults. Obesity 18:300–307CrossRefPubMed Dennis EA, Dengo AL, Comber DL, Flack KD, Savla J, Davy KP, Davy BM (2010) Water consumption increases weight loss during a hypocaloric diet intervention in middle-aged and older adults. Obesity 18:300–307CrossRefPubMed
23.
go back to reference Roussel R, Fezeu L, Bouby N, Balkau B, Lantieri O, Alhenc-Gelas F, Marre M, Bankir L, Group DESIRS. (2011) Low water intake and risk for new-onset hyperglycemia. Diabetes Care 34:2551–2554CrossRefPubMedPubMedCentral Roussel R, Fezeu L, Bouby N, Balkau B, Lantieri O, Alhenc-Gelas F, Marre M, Bankir L, Group DESIRS. (2011) Low water intake and risk for new-onset hyperglycemia. Diabetes Care 34:2551–2554CrossRefPubMedPubMedCentral
24.
go back to reference Bouby N, Bachmann S, Bichet D, Bankir L (1990) Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 258:F973–F979PubMed Bouby N, Bachmann S, Bichet D, Bankir L (1990) Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 258:F973–F979PubMed
25.
go back to reference Strippoli GF, Craig JC, Rochtchina E, Flood VM, Wang JJ, Mitchell P (2011) Fluid and nutrient intake and risk of chronic kidney disease. Nephrology 16:326–334CrossRefPubMed Strippoli GF, Craig JC, Rochtchina E, Flood VM, Wang JJ, Mitchell P (2011) Fluid and nutrient intake and risk of chronic kidney disease. Nephrology 16:326–334CrossRefPubMed
26.
go back to reference Clark WF, Sontrop JM, Macnab JJ, Suri RS, Moist L, Salvadori M, Garg AX (2011) Urine volume and change in estimated GFR in a community-based cohort study. Clin J Am Soc Nephrol 6:2634–2641CrossRefPubMedPubMedCentral Clark WF, Sontrop JM, Macnab JJ, Suri RS, Moist L, Salvadori M, Garg AX (2011) Urine volume and change in estimated GFR in a community-based cohort study. Clin J Am Soc Nephrol 6:2634–2641CrossRefPubMedPubMedCentral
27.
go back to reference Fedorowski A, Stavenow L, Hedblad B, Berglund G, Nilsson PM, Melander O (2010) Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project). Eur Heart J 31:85–91CrossRefPubMed Fedorowski A, Stavenow L, Hedblad B, Berglund G, Nilsson PM, Melander O (2010) Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project). Eur Heart J 31:85–91CrossRefPubMed
28.
go back to reference Fenske W, Stork S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B (2009) Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 94:123–129CrossRefPubMed Fenske W, Stork S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B (2009) Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 94:123–129CrossRefPubMed
29.
go back to reference Roussel R, Matallah N, Bouby N, El Boustany R, Potier L, Fumeron F, Mohammedi K, Balkau B, Marre M, Bankir L, Velho G (2015) Plasma copeptin and decline in renal function in a cohort from the community: the prospective D.E.S.I.R. study. Am J Nephrol 42:107–114CrossRefPubMed Roussel R, Matallah N, Bouby N, El Boustany R, Potier L, Fumeron F, Mohammedi K, Balkau B, Marre M, Bankir L, Velho G (2015) Plasma copeptin and decline in renal function in a cohort from the community: the prospective D.E.S.I.R. study. Am J Nephrol 42:107–114CrossRefPubMed
30.
go back to reference Tasevska I, Enhorning S, Christensson A, Persson M, Nilsson PM, Melander O (2016) Increased levels of copeptin, a surrogate marker of arginine vasopressin, are associated with an increased risk of chronic kidney disease in a general population. Am J Nephrol 44:22–28CrossRefPubMed Tasevska I, Enhorning S, Christensson A, Persson M, Nilsson PM, Melander O (2016) Increased levels of copeptin, a surrogate marker of arginine vasopressin, are associated with an increased risk of chronic kidney disease in a general population. Am J Nephrol 44:22–28CrossRefPubMed
31.
go back to reference Jochberger S, Dorler J, Luckner G, Mayr VD, Wenzel V, Ulmer H, Morgenthaler NG, Hasibeder WR, Dunser MW (2009) The vasopressin and copeptin response to infection, severe sepsis, and septic shock. Crit Care Med 37:476–482CrossRefPubMed Jochberger S, Dorler J, Luckner G, Mayr VD, Wenzel V, Ulmer H, Morgenthaler NG, Hasibeder WR, Dunser MW (2009) The vasopressin and copeptin response to infection, severe sepsis, and septic shock. Crit Care Med 37:476–482CrossRefPubMed
32.
go back to reference Stoiser B, Mortl D, Hulsmann M, Berger R, Struck J, Morgenthaler NG, Bergmann A, Pacher R (2006) Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Investig 36:771–778CrossRef Stoiser B, Mortl D, Hulsmann M, Berger R, Struck J, Morgenthaler NG, Bergmann A, Pacher R (2006) Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Investig 36:771–778CrossRef
33.
go back to reference Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, Roth A, Bickel C, Baldus S, Sinning CR, Wild PS, Lubos E, Peetz D, Kunde J, Hartmann O, Bergmann A, Post F, Lackner KJ, Genth-Zotz S, Nicaud V, Tiret L, Munzel TF, Blankenberg S (2010) Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 55:2096–2106CrossRefPubMed Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, Roth A, Bickel C, Baldus S, Sinning CR, Wild PS, Lubos E, Peetz D, Kunde J, Hartmann O, Bergmann A, Post F, Lackner KJ, Genth-Zotz S, Nicaud V, Tiret L, Munzel TF, Blankenberg S (2010) Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 55:2096–2106CrossRefPubMed
34.
go back to reference Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M (2007) Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 28:219–226CrossRefPubMed Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M (2007) Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 28:219–226CrossRefPubMed
35.
go back to reference Roussel R, El Boustany R, Bouby N, Potier L, Fumeron F, Mohammedi K, Balkau B, Tichet J, Bankir L, Marre M, Velho G (2016) Plasma copeptin, AVP gene variants, and incidence of type 2 diabetes in a cohort from the community. J Clin Endocrinol Metab 101:2432–2439CrossRefPubMedPubMedCentral Roussel R, El Boustany R, Bouby N, Potier L, Fumeron F, Mohammedi K, Balkau B, Tichet J, Bankir L, Marre M, Velho G (2016) Plasma copeptin, AVP gene variants, and incidence of type 2 diabetes in a cohort from the community. J Clin Endocrinol Metab 101:2432–2439CrossRefPubMedPubMedCentral
36.
go back to reference Cryer PE (2012) Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 153:1039–1048CrossRefPubMed Cryer PE (2012) Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 153:1039–1048CrossRefPubMed
37.
go back to reference Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB (1987) Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106–110CrossRefPubMed Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB (1987) Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106–110CrossRefPubMed
38.
go back to reference Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA (2000) Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053–4059PubMed Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA (2000) Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053–4059PubMed
39.
go back to reference Ahren B (2009) Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women. Diabetes 58:726–731CrossRefPubMedPubMedCentral Ahren B (2009) Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women. Diabetes 58:726–731CrossRefPubMedPubMedCentral
40.
go back to reference Taveau C, Chollet C, Bichet DG, Velho G, Guillon G, Corbani M, Roussel R, Bankir L, Melander O, Bouby N (2017) Acute and chronic hyperglycemic effects of vasopressin in normal rats, involvement of V1a receptors. Am J Physiol Endocrinol Metab 312:E127–E135CrossRefPubMed Taveau C, Chollet C, Bichet DG, Velho G, Guillon G, Corbani M, Roussel R, Bankir L, Melander O, Bouby N (2017) Acute and chronic hyperglycemic effects of vasopressin in normal rats, involvement of V1a receptors. Am J Physiol Endocrinol Metab 312:E127–E135CrossRefPubMed
41.
go back to reference Bouby N, Ahloulay M, Nsegbe E, Dechaux M, Schmitt F, Bankir L (1996) Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action. J Am Soc Nephrol 7:842–851PubMed Bouby N, Ahloulay M, Nsegbe E, Dechaux M, Schmitt F, Bankir L (1996) Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action. J Am Soc Nephrol 7:842–851PubMed
Metadata
Title
Effects of hydration on plasma copeptin, glycemia and gluco-regulatory hormones: a water intervention in humans
Authors
Sofia Enhörning
Irina Tasevska
Ronan Roussel
Nadine Bouby
Margaretha Persson
Philippe Burri
Lise Bankir
Olle Melander
Publication date
01-02-2019
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nutrition / Issue 1/2019
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-017-1595-8

Other articles of this Issue 1/2019

European Journal of Nutrition 1/2019 Go to the issue